Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (19182)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 26, 2019 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 2019; 7(4): 405-418 [PMID: 30842952 DOI: 10.12998/wjcc.v7.i4.405] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v7/i4/405.htm |
| Number | Citing Articles |
| 1 |
Hailey Brown, Daria Esterházy. Intestinal immune compartmentalization: implications of tissue specific determinants in health and disease. Mucosal Immunology 2021; 14(6): 1259 doi: 10.1038/s41385-021-00420-8
|
| 2 |
Octavio Gómez-Escudero. Benign Anorectal Disorders - An Update. 2023; doi: 10.5772/intechopen.103734
|
| 3 |
Tsvetelina Velikova, Boris Krastev, Milena Gulinac, Miroslav Zashev, Vasko Graklanov, Milena Peruhova. New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis. World Journal of Clinical Cases 2024; 12(6): 1050-1062 doi: 10.12998/wjcc.v12.i6.1050
Abstract(104) |
Core Tip(88) |
Full Article(HTML)(668)
|
Full Article with Cover (PDF)-6262K(81)
|
Full Article (Word)-2309K(11)
|
Audio-266K(0)
|
Peer-Review Report-321K(8)
|
Answering Reviewers-199K(30)
|
Supplementary Material-160K(12)
|
Full Article (PDF)-6032K(38)
|
Full Article (XML)-184K(13)
|
Times Cited (0)
|
Total Visits (1397)
|
Open
|
| 4 |
Kanika Sehgal, Sahil Khanna. Gut microbiome and checkpoint inhibitor colitis. Intestinal Research 2021; 19(4): 360 doi: 10.5217/ir.2020.00116
|
| 5 |
Lise Høj Omland, Dag Rune Stormoen, Line Hammer Dohn, Andreas Carus, Anne Birgitte Als, Niels Viggo Jensen, Gry Assam Taarnhøj, Anders Tolver, Helle Pappot. Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark. Bladder Cancer 2021; 7(4): 413 doi: 10.3233/BLC-211523
|
| 6 |
Yi-Jung Huang, Kai-Wen Ho, Tian-Lu Cheng, Yen-Tseng Wang, Shi-Wei Chao, Bo-Cheng Huang, Yu-Shu Chao, Chia-Yu Lin, Yun-Han Hsu, Fang-Ming Chen, Chih-Hung Chuang. Selective activation of IFNγ–ipilimumab enhances the therapeutic effect and safety of ipilimumab. International Journal of Biological Macromolecules 2024; 265: 130945 doi: 10.1016/j.ijbiomac.2024.130945
|
| 7 |
Pierre-François Simand, Nathalie Baudoux, Thibaud Kössler. Immunotherapy and Gastrointestinal Toxicities. Praxis 2023; 112(3): 172 doi: 10.1024/1661-8157/a003977
|
| 8 |
Patricia Sanz-Segura, Paula García-Cámara, Eva Fernández-Bonilla, José Miguel Arbonés-Mainar, Vanesa Bernal Monterde. Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacional. Gastroenterología y Hepatología 2021; 44(4): 261 doi: 10.1016/j.gastrohep.2020.07.009
|
| 9 |
Yen‐Chun Liu, Cheng‐Tang Chiu, Ren‐Chin Wu, Chao‐Wei Hsu, Chun‐Wei Chen, Puo‐Hsien Le, Chia‐Jung Kuo. Atezolizumab‐associated colitis mimic inflammatory bowel disease: A case report. Advances in Digestive Medicine 2023; 10(1): 50 doi: 10.1002/aid2.13303
|
| 10 |
Taylor Halsey, Gabriel Ologun, Jennifer Wargo, Robert R. Jenq. Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. Seminars in Hematology 2020; 57(1): 13 doi: 10.1053/j.seminhematol.2020.05.002
|
| 11 |
M. Lisa Zhang, Vikram Deshpande. Histopathology of Gastrointestinal Immune-related Adverse Events. American Journal of Surgical Pathology 2022; 46(1): e15 doi: 10.1097/PAS.0000000000001730
|
| 12 |
Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.779691
|
| 13 |
Sofia España Fernandez, Chen Sun, Carme Solé-Blanch, Aram Boada, Anna Martínez-Cardús, José Luis Manzano. Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?. Pharmaceutics 2023; 15(3): 823 doi: 10.3390/pharmaceutics15030823
|
| 14 |
Viktor Grünwald, James Larkin, Javier Puente, Jens Bedke, Camillo Porta. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma. Clinical Genitourinary Cancer 2024; 22(2): 394 doi: 10.1016/j.clgc.2023.12.010
|
| 15 |
Jacob Dehinsilu, Chrysi Sergaki, Gregory Amos, Vanessa Fontana, Munir Pirmohamed. The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. Frontiers in Microbiomes 2023; 2 doi: 10.3389/frmbi.2023.1061193
|
| 16 |
Hourieh Sadrekarimi, Zhanna R. Gardanova, Morteza Bakhshesh, Farnoosh Ebrahimzadeh, Amirhossein Fakhre Yaseri, Lakshmi Thangavelu, Zahra Hasanpoor, Firoozeh Abolhasani Zadeh, Mohammad Saeed Kahrizi. Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora. Journal of Translational Medicine 2022; 20(1) doi: 10.1186/s12967-022-03492-7
|
| 17 |
Guili Huang, Songqing Liu, Jie Dong, Xin Xi, Rui Kong, Wenjun Li, Qian Du. PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.974376
|
| 18 |
Sarah Kim, Gezim Lahu, Majid Vakilynejad, Theodoros G. Soldatos, David B. Jackson, Lawrence J. Lesko, Mirjam N. Trame. Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors. Clinical and Translational Science 2022; 15(6): 1430 doi: 10.1111/cts.13254
|
| 19 |
Hiroyuki Ando, Kunihiro Suzuki, Toyoshi Yanagihara. Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. Biomedicines 2021; 9(10): 1484 doi: 10.3390/biomedicines9101484
|
| 20 |
|
| 21 |
Masaya Iwamuro, Takehiro Tanaka, Yoshiyasu Kono, Seiji Kawano, Horoyuki Okada. Multiple White Plaques in the Esophagus: A Possible Case of Esophageal Mucosal Alteration Associated With Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Cureus 2022; doi: 10.7759/cureus.32710
|
| 22 |
Pablo Garcia, Margaret R Stedman, Shayli Merlo, Aydin Kaghazchi, Sunil Reddy, Tamiko R Katsumoto, Shuchi Anand. Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes. Journal of Onco-Nephrology 2023; 7(2): 57 doi: 10.1177/23993693231161875
|
| 23 |
Lars Michel, Tienush Rassaf, Matthias Totzeck. Cardiotoxicity from immune checkpoint inhibitors. IJC Heart & Vasculature 2019; 25: 100420 doi: 10.1016/j.ijcha.2019.100420
|
| 24 |
Natalie Farha, Motasem Alkhayyat, Adrian Lindsey, Emad Mansoor, Mohannad Abou Saleh. Immune checkpoint inhibitor induced colitis: A nationwide population-based study. Clinics and Research in Hepatology and Gastroenterology 2022; 46(1): 101778 doi: 10.1016/j.clinre.2021.101778
|
| 25 |
Ahmed Hashim, Piers E M Patten, Andrea Kuhnl, Marc L Ooft, Bu’Hussain Hayee, Robin Sanderson. Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy. Inflammatory Bowel Diseases 2021; 27(4): e45 doi: 10.1093/ibd/izaa320
|
| 26 |
Sunitha Shyam Sunder, Umesh C. Sharma, Saraswati Pokharel. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01469-6
|
| 27 |
Mary O’Reilly, Gregory Mellotte, Barbara Ryan, Anthony O’Connor. Gastrointestinal side effects of cancer treatments. Therapeutic Advances in Chronic Disease 2020; 11: 204062232097035 doi: 10.1177/2040622320970354
|
| 28 |
Kelsey Sheehan, Christina Price, Navid Hafez. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. The Cancer Journal 2020; 26(6): 537 doi: 10.1097/PPO.0000000000000492
|
| 29 |
Genesis Perez Del Nogal, Neha Patel. Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab. ACG Case Reports Journal 2022; 9(12): e00946 doi: 10.14309/crj.0000000000000946
|
| 30 |
Carolina A. Ferreira, Pedram Heidari, Bahar Ataeinia, Nicoleta Sinevici, Meghan E. Sise, Robert B. Colvin, Eric Wehrenberg-Klee, Umar Mahmood. Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical Cancer Research 2021; 27(19): 5353 doi: 10.1158/1078-0432.CCR-20-4641
|
| 31 |
Ashley N. Tran, Melinda Wang, Melanie Hundt, Rishika Chugh, Jonathan Ohm, Alyssa Grimshaw, Maria Ciarleglio, Kenneth W. Hung, Deborah D. Proctor, Christina C. Price, Loren Laine, Badr Al-Bawardy. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal of Immunotherapy 2021; 44(8): 325 doi: 10.1097/CJI.0000000000000383
|
| 32 |
Antonella Arcadu, Margherita S. Silani, Francesco Amati, Andrea Gramegna, Francesco Blasi, Stefano Aliberti. Lung Diseases and Cancer. 2022; : 299 doi: 10.1183/2312508X.10020821
|
| 33 |
Alfonso Reginelli, Angelo Sangiovanni, Giovanna Vacca, Maria Paola Belfiore, Maria Pignatiello, Giuseppe Viscardi, Alfredo Clemente, Fabrizio Urraro, Salvatore Cappabianca. Chemotherapy-induced bowel ischemia: diagnostic imaging overview. Abdominal Radiology 2022; 47(5): 1556 doi: 10.1007/s00261-021-03024-9
|
| 34 |
Mohammed Al Nuhait, Eshtyag Bajnaid, Abdulmalik Al Otaibi, Abdullah Al Shammari, Yousef Al Awlah. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia. Science Progress 2021; 104(1): 003685042199730 doi: 10.1177/0036850421997302
|
| 35 |
Xinyue Dai, Zhaoshuo Wang, Miao Fan, Huifang Liu, Xinjian Yang, Xueyi Wang, Xiaohan Zhou, Yunlu Dai, Jinchao Zhang, Zhenhua Li. PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis. Extracellular Vesicle 2022; 1: 100012 doi: 10.1016/j.vesic.2022.100012
|
| 36 |
Eli P. Darnell, Meghan J. Mooradian, Erez N. Baruch, Melis Yilmaz, Kerry L. Reynolds. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Current Oncology Reports 2020; 22(4) doi: 10.1007/s11912-020-0897-9
|
| 37 |
Bo Hu, Xiao-Bo Yang, Xin-Ting Sang. Liver graft rejection following immune checkpoint inhibitors treatment: a review. Medical Oncology 2019; 36(11) doi: 10.1007/s12032-019-1316-7
|
| 38 |
Marina Chulkina, Ellen J. Beswick, Irina V. Pinchuk. Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation. International Journal of Molecular Sciences 2020; 21(23): 9165 doi: 10.3390/ijms21239165
|
| 39 |
Frederic Jungbauer, Annette Affolter, Christoph Brochhausen, Anne Lammert, Sonja Ludwig, Kirsten Merx, Nicole Rotter, Lena Huber. Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1287178
|
| 40 |
Nadine Petitpain, Ferdinando D’Amico, Melissa Yelehe‐Okouma, Jean‐Yves Jouzeau, Patrick Netter, Laurent Peyrin‐Biroulet, Pierre Gillet. IL‐17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. Clinical Pharmacology & Therapeutics 2021; 110(1): 159 doi: 10.1002/cpt.2155
|
| 41 |
Michelle Moore, Roger M Feakins, Gregory Y Lauwers. Non-neoplastic colorectal disease biopsies: evaluation and differential diagnosis. Journal of Clinical Pathology 2020; 73(12): 783 doi: 10.1136/jclinpath-2020-206794
|
| 42 |
Rocio Sedano, Daniel Cabrera, Andrea Jiménez, Christopher Ma, Vipul Jairath, Marco Arrese, Juan Pablo Arab. Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. American Journal of Gastroenterology 2022; 117(12): 1917 doi: 10.14309/ajg.0000000000001983
|
| 43 |
Emiko Mizoguchi, Takayuki Sadanaga, Linda Nanni, Siyuan Wang, Atsushi Mizoguchi. Recently Updated Role of Chitinase 3-like 1 on Various Cell Types as a Major Influencer of Chronic Inflammation. Cells 2024; 13(8): 678 doi: 10.3390/cells13080678
|
| 44 |
Hasti Gholami, John A. Chmiel, Jeremy P. Burton, Saman Maleki Vareki. The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy. Cancers 2023; 15(4): 1300 doi: 10.3390/cancers15041300
|
| 45 |
Hannah Walton, Samantha Hopkins, Alan Shand, Shahida Din. Immunotherapy-induced coeliac disease in curative lung cancer. BMJ Case Reports 2021; 14(9): e243406 doi: 10.1136/bcr-2021-243406
|
| 46 |
Rejath Jose, Jasveen Kaur, Theophany Blanco, Samantha Ehrlich , Michael Marcelin. Pembrolizumab-Induced Colitis and Diarrhea in the Treatment of Sporadic Colorectal Cancer: A Case Report. Cureus 2024; doi: 10.7759/cureus.52636
|
| 47 |
Ali Pourvaziri, Anushri Parakh, Pierpaolo Biondetti, Dushyant Sahani, Avinash Kambadakone. Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists. Abdominal Radiology 2020; 45(9): 2624 doi: 10.1007/s00261-020-02531-5
|
| 48 |
Maham Farshidpour, William Hutson. Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives. Middle East Journal of Digestive Diseases 2022; 14(2): 244 doi: 10.34172/mejdd.2022.279
|
| 49 |
Shikai Yan, Leilei Yu, Fengwei Tian, Jianxin Zhao, Wei Chen, Haiqin Chen, Qixiao Zhai.
Ligilactobacillus salivarius CCFM 1266 modulates gut microbiota and GPR109a-mediated immune suppression to attenuate immune checkpoint blockade-induced colitis. Food & Function 2023; 14(23): 10549 doi: 10.1039/D3FO03867J
|
| 50 |
Satya Das, Kristen K. Ciombor, Sigurdis Haraldsdottir, Yoanna Pumpalova, Ibrahim H. Sahin, G. Pineda, Yu Shyr, E.P. Lin, Chih-Yuan Hsu, Shih-Kai Chu, Laura W. Goff, Dana B. Cardin, Mehmet A. Bilen, George A. Fisher, Christina Wu, Jordan Berlin. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. The Oncologist 2020; 25(8): 669 doi: 10.1634/theoncologist.2019-0637
|
| 51 |
Darina Kohoutova, Dominic Worku, Hala Aziz, Julian Teare, Justin Weir, James Larkin. Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. Cells 2021; 10(2): 327 doi: 10.3390/cells10020327
|
| 52 |
Takahito Kondo, Munehide Nakatsugawa, Mitsuru Okubo, Hironori Nakamura, Daisuke Yunaiyama, Midori Wakiya, Atsuo Takeda, Naiue Kikawada, Takuma Kishida, Miwako Someya, Shigekazu Yoshida, Yasuo Ogawa, Kiyoaki Tsukahara. Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation. Ear, Nose & Throat Journal 2021; : 014556132110310 doi: 10.1177/01455613211031025
|
| 53 |
Nira A Krasnow, Donald F Chute, Ayo S Falade, Crystal M North, Kerry L Reynolds, Michael L Dougan. Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis. Immunotherapy 2023; 15(12): 913 doi: 10.2217/imt-2022-0245
|
| 54 |
Fatih Albayrak, Mustafa Gür, Ahmet Karataş, Süleyman Serdar Koca, Bünyamin Kısacık. Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?. Reumatología Clínica 2024; 20(3): 123 doi: 10.1016/j.reuma.2023.11.004
|
| 55 |
O. Gómez-Escudero. Enterocolitis y otras manifestaciones de toxicidad gastrointestinal asociada a inmunoterapia y terapia blanco: una revisión para el gastroenterólogo. Revista de Gastroenterología de México 2024; 89(1): 89 doi: 10.1016/j.rgmx.2023.11.001
|
| 56 |
Xavier L. Baldwin, Philip M. Spanheimer, Stephanie Downs-Canner. A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research 2023; 281: 289 doi: 10.1016/j.jss.2022.08.040
|
| 57 |
Beth A. Helmink, Christina L. Roland, Colleen M. Kiernan, Jennifer A. Wargo. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Annals of Surgical Oncology 2020; 27(5): 1533 doi: 10.1245/s10434-019-08183-0
|
| 58 |
Koji Yoshino, Takayuki Nakayama, Ayumu Ito, Eiichi Sato, Shigehisa Kitano. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6138-7
|
| 59 |
Zhigang Yuan, Daniel Fernandez, Jasreman Dhillon, Julieta Abraham-Miranda, Shivanshu Awasthi, Youngchul Kim, Jingsong Zhang, Rohit Jain, Amparo Serna, Julio M. Pow-Sang, Michael Poch, Roger Li, Brandon Manley, Angelina Fink, Arash Naghavi, Javier F. Torres-Roca, G. Daniel Grass, Sungjune Kim, Kujtim Latifi, Dylan Hunt, Peter A. S. Johnstone, Kosj Yamoah. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer and Prostatic Diseases 2021; 24(1): 140 doi: 10.1038/s41391-020-0254-y
|
| 60 |
Abdulaali R. Almutairi, Marion Slack, Brian L. Erstad, Ali McBride, Ivo Abraham. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database. Therapeutic Advances in Drug Safety 2021; 12: 204209862199127 doi: 10.1177/2042098621991279
|
| 61 |
Sadie De Silva, Harry Trieu, Anand Rajan, Yu Liang, James L Lin, Trilokesh D Kidambi. Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy‐mediated colitis: A cross‐sectional study. Journal of Gastroenterology and Hepatology 2022; 37(2): 284 doi: 10.1111/jgh.15691
|
| 62 |
O. Gómez-Escudero, J.M. Remes-Troche. Approach to the adult patient with chronic diarrhea: A literature review. Revista de Gastroenterología de México (English Edition) 2021; 86(4): 387 doi: 10.1016/j.rgmxen.2021.08.007
|
| 63 |
Andrea Pagan, Yadis M Arroyo-Martinez, Ankita Tandon , Carlos Bertran-Rodriguez, Jeffrey Gill. Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis. Cureus 2020; doi: 10.7759/cureus.8613
|
| 64 |
Thomas S.C. Ng, Miles A. Miller. Engineering Technologies and Clinical Translation. 2022; : 427 doi: 10.1016/B978-0-323-90949-5.00013-9
|
| 65 |
Jocelyn R. Farmer. Testing Immune-Related Adverse Events in Cancer Immunotherapy. Clinics in Laboratory Medicine 2019; 39(4): 669 doi: 10.1016/j.cll.2019.07.012
|
| 66 |
Manon Verhé, Thomas De Somer, Barbara Defoort, Erik Vanderstraeten, Els Monsaert, Vincent Bouderez, Stefanie Dias, Danielle Delombaerde, Christof Vulsteke, Christophe Van Steenkiste. The Role of Abdominal Surgery in Refractory Immune Checkpoint Inhibitor Enterocolitis: A Case Report. Case Reports in Oncology 2023; : 453 doi: 10.1159/000530832
|
| 67 |
Fatih Albayrak, Mustafa Gür, Ahmet Karataş, Süleyman Serdar Koca, Bünyamin Kısacık. Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease?. Reumatología Clínica (English Edition) 2024; 20(3): 123 doi: 10.1016/j.reumae.2023.11.002
|
| 68 |
Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, Md. Noor Alam, Md. Mohaimenul Islam, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya, Simona Gabriela Bungau. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules 2022; 27(12): 3798 doi: 10.3390/molecules27123798
|
| 69 |
Cynthia Liu, Rajan Amin, Malek Shatila, Nicholas Short, Mehmet Altan, Amishi Shah, Omar Alhalabi, Pablo Okhuysen, Anusha S. Thomas, Yinghong Wang. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. Journal of Cancer Research and Clinical Oncology 2023; 149(7): 3965 doi: 10.1007/s00432-022-04316-3
|
| 70 |
Randy Adiwinata, Kevin Tandarto, Caroline Tanadi, Bradley Jimmy Waleleng, Harlinda Haroen, Linda Rotty, Fandy Gosal, Luciana Rotty, Cecilia Hendratta, Pearla Lasut, Jeanne Winarta, Andrew Waleleng, Paulus Simadibrata, Marcellus Simadibrata. Immune Checkpoint Inhibitor Colitis, a Rising Issue in Targeted Cancer Therapy Era: A Literature Review. Romanian Journal of Internal Medicine 2024; 0(0) doi: 10.2478/rjim-2024-0015
|
| 71 |
Hirotaka Miyashita, Takahisa Mikami, Sera Satoi, Christina Cruz, Matthew D. Galsky. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. Journal of Immunotherapy 2020; 43(9): 291 doi: 10.1097/CJI.0000000000000339
|
| 72 |
Oliver Oey, Yu-Yang Liu, Angela Felicia Sunjaya, Daniel Martin Simadibrata, Muhammad Adnan Khattak, Elin Gray. Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review. World Journal of Clinical Oncology 2022; 13(11): 929-942 doi: 10.5306/wjco.v13.i11.929
|
| 73 |
Pooja Middha, Rohit Thummalapalli, Michael J. Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A. Bejan, Eduardo Cardenas, Christina J. Falcon, David M. Faleck, Natasha B. Leighl, Penelope A. Bradbury, Frances A. Shepherd, Adrian G. Sacher, Lawson Eng, Matthew A. Gubens, Scott Huntsman, Douglas B. Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M. Lovly, Megan H. Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M. Balko, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis. Nature Communications 2024; 15(1) doi: 10.1038/s41467-023-44512-4
|
| 74 |
Dominic Adam Worku, Victoria Hewitt. The role and economics of immunotherapy in solid tumour management. Journal of Oncology Pharmacy Practice 2020; 26(8): 2020 doi: 10.1177/1078155220963190
|
| 75 |
Barbara Hollander, Shruti Khurana, Jake S. Jacob, Melmet Altan, Jianbo Wang, Dan Zhao, Krishnavathana Varatharajalu, Mazen Alasadi, Anusha S. Thomas, Yinghong Wang. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. Journal of Cancer Research and Clinical Oncology 2023; 149(7): 3637 doi: 10.1007/s00432-022-04116-9
|
| 76 |
Yibing Wei, Dingka Song, Ran Wang, Tingting Li, Hui Wang, Xiaoguang Li. Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1038710
|
| 77 |
Shruti Gupta, Prakash Gudsoorkar, Kenar D. Jhaveri. Acute Kidney Injury in Critically Ill Patients with Cancer. Clinical Journal of the American Society of Nephrology 2022; 17(9): 1385 doi: 10.2215/CJN.15681221
|
| 78 |
Sing-Ting Wang, Ming-Yu Lien. Severe colitis induced by pembrolizumab in a patient with advanced hypopharyngeal squamous cell carcinoma: A case report of an immune-related adverse event. Journal of Cancer Research and Practice 2021; 8(3): 113 doi: 10.4103/JCRP.JCRP_5_21
|
| 79 |
Jialin Qu, Man Jiang, Li Wang, Deze Zhao, Kang Qin, Yun Wang, Junyan Tao, Xiaochun Zhang. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. Biomedicine & Pharmacotherapy 2020; 127: 109996 doi: 10.1016/j.biopha.2020.109996
|
| 80 |
Gurhan Sisman, Erol Barbur, Didem Saka, Sibel Erdamar Cetin. Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection. Cancer Immunology, Immunotherapy 2021; 70(8): 2385 doi: 10.1007/s00262-020-02815-1
|
| 81 |
Andrew Nashed, Shijun Zhang, Chien-Wei Chiang, M. Zitu, Gregory A. Otterson, Carolyn J. Presley, Kari Kendra, Sandip H. Patel, Andrew Johns, Mingjia Li, Madison Grogan, Gabrielle Lopez, Dwight H. Owen, Lang Li. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunology, Immunotherapy 2021; 70(10): 2761 doi: 10.1007/s00262-021-02880-0
|
| 82 |
Paola Michelle Calle Sarmiento. Immune Checkpoint Inhibitor-Induced Colitis: How Long Does the Threat Last?. Cureus 2023; doi: 10.7759/cureus.40627
|
| 83 |
Grace Wakabayashi, Yu-Ching Lee, Frank Luh, Chun-Nan Kuo, Wei-Chiao Chang, Yun Yen. Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science 2019; 26(1) doi: 10.1186/s12929-019-0588-8
|
| 84 |
O. Gómez-Escudero, J.M. Remes-Troche. Abordaje de la diarrea crónica en el adulto: Revisión de la literatura. Revista de Gastroenterología de México 2021; 86(4): 387 doi: 10.1016/j.rgmx.2021.02.002
|
| 85 |
Hamzah Abu-Sbeih, Yinghong Wang. Immunotherapy. Advances in Experimental Medicine and Biology 2020; 1244: 247 doi: 10.1007/978-3-030-41008-7_12
|
| 86 |
Gerard Grau, Ariadna Altadill, Eduard Brunet-Mas, Xavier Calvet. Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis. Gastroenterología y Hepatología (English Edition) 2024; 47(1): 72 doi: 10.1016/j.gastre.2023.01.011
|
| 87 |
C. Duffin, S. Mirpour, T. Catanzano, C. Moore. Radiologic Imaging of Bowel Infections. Seminars in Ultrasound, CT and MRI 2020; 41(1): 33 doi: 10.1053/j.sult.2019.10.004
|
| 88 |
Anusha Shirwaikar Thomas, Stephen Hanauer, Yinghong Wang. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2023; 21(4): 878 doi: 10.1016/j.cgh.2022.10.004
|
| 89 |
María Mangas Losada, Leonardo Romero Robles, Alejandro Mendoza Melero, Irene García Megías, Amós Villanueva Torres, Puy Garrastachu Zumarán, Xavier Boulvard Chollet, Egesta Lopci, Rafael Ramírez Lasanta, Roberto C. Delgado Bolton. [18F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy. Diagnostics 2023; 13(5): 978 doi: 10.3390/diagnostics13050978
|
| 90 |
Corinne Frere, Carme Font, Francis Esposito, Benjamin Crichi, Philippe Girard, Nicolas Janus. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. Supportive Care in Cancer 2022; 30(4): 2919 doi: 10.1007/s00520-021-06598-8
|
| 91 |
Eva Zhang, Christopher Kiely, Neomal Sandanayake, Stephen Tattersall. Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis. JGH Open 2021; 5(5): 558 doi: 10.1002/jgh3.12531
|
| 92 |
Anusha Shirwaikar Thomas, Yinghong Wang. Managing Immunotherapy Related Organ Toxicities. 2022; : 81 doi: 10.1007/978-3-031-00241-0_5
|
| 93 |
G. S. Braun, M. Kirschner, A. Rübben, R. U. Wahl, K. Amann, K. Benesova, J. Leipe. Nebenwirkungen neuer onkologischer Immuntherapien. Der Nephrologe 2020; 15(3): 191 doi: 10.1007/s11560-020-00424-8
|
| 94 |
John Turchini, Loretta Sioson, Adele Clarkson, Amy Sheen, Anthony J. Gill. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours. Endocrine Pathology 2021; 32(3): 408 doi: 10.1007/s12022-021-09673-2
|
| 95 |
Shinsuke Otagiri, Takehiko Katsurada, Kana Yamanashi, Kensuke Sakurai, Michiko T Sato, Jun Sakakibara‐Konishi, Naoya Sakamoto. Immune checkpoint inhibitor‐induced enteritis assessed using capsule endoscopy. JGH Open 2020; 4(6): 1231 doi: 10.1002/jgh3.12392
|
| 96 |
Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. International Journal of Molecular Sciences 2023; 24(14): 11504 doi: 10.3390/ijms241411504
|
| 97 |
Jean Terrier, Alan Relecom, Simon Borgeaud, Claire Bridel, Jörg Seebach, Frédéric Assal, Jean-Luc Reny, Jacques Serratrice. A bilateral aseptic pyogenic ventriculitis following a course of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor treatment for metastatic small cell lung cancer. Therapies 2022; 77(6): 754 doi: 10.1016/j.therap.2022.05.002
|
| 98 |
Katharina Sommer, Svenja Wulf, Julia Gallwas. SOP Maßnahmen bei Diarrhö unter Therapie mit Checkpoint-Inhibitoren. Frauenheilkunde up2date 2023; 17(02): 119 doi: 10.1055/a-1931-8920
|
| 99 |
Kathy Tin, Aikaterini Papamanoli, George Psevdos, Zeena Lobo, Olga Kaplun. New-Onset Diarrheal Illness in a Patient With Ulcerative Colitis Receiving Nivolumab for Lung Adenocarcinoma. Infectious Diseases in Clinical Practice 2022; 30(1) doi: 10.1097/IPC.0000000000001084
|
| 100 |
Lei Han, Guangxin Li, Huihui Li, Lei Zhao. Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. Chemotherapy 2023; 68(1): 1 doi: 10.1159/000523904
|
| 101 |
Takahiro Fuji, Jun Arai, Yumi Otoyama, Yuta Nio, Ikuya Sugiura, Yoko Nakajima, Atsushi Kajiwara, Yuki Ichikawa, Shojiro Uozumi, Yuu Shimozuma, Manabu Uchikoshi, Masashi Sakaki, Hisako Nozawa, Kenji Momo, Tadanori Sasaki, Hitoshi Yoshida. A Case of Hepatocellular Carcinoma Successfully Resumed Atezolizumab and Bevacizumab After Associated Grade 3 Diarrhea and Grade 2 Colitis: Case Report and Literature Review. OncoTargets and Therapy 2022; : 1281 doi: 10.2147/OTT.S383769
|
| 102 |
Yong-Zhe Hou, Qin Zhang, Hai Bai, Tao Wu, Ya-Jie Chen. Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy. World Journal of Clinical Cases 2023; 11(7): 1458-1466 doi: 10.12998/wjcc.v11.i7.1458
Abstract(351) |
Core Tip(220) |
Full Article(HTML)(1143)
|
Full Article (PDF)-991K(93)
|
Full Article (Word)-339K(23)
|
Audio-455K(6)
|
Peer-Review Report-259K(20)
|
Answering Reviewers-55K(30)
|
Times Cited (0)
|
Total Visits (3262)
|
Open
|
| 103 |
Dorte Lisbet Nielsen, Carsten Bogh Juhl, Inna Markovna Chen, Lauge Kellermann, Ole Haagen Nielsen. Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treatment Reviews 2022; 109: 102440 doi: 10.1016/j.ctrv.2022.102440
|
| 104 |
Minnie Au, Arvind Rajagopalan, Derrick Tee, Hamish Philpott. Immune checkpoint inhibitor colitis with concurrent cytomegalovirus reactivation. Internal Medicine Journal 2022; 52(3): 504 doi: 10.1111/imj.15714
|
| 105 |
Ahmed Bakhshwin, Jessica Robertson, Mrinal Sarwate, Daniel Roberts. Perforating Colitis Secondary to Immune Checkpoint Inhibitor Use in a Patient With Pericolonic Involvement by Rosai-Dorfman Disease. ACG Case Reports Journal 2022; 9(12): e00900 doi: 10.14309/crj.0000000000000900
|
| 106 |
Eva Rajha, Patrick Chaftari, Mona Kamal, Julian Maamari, Christopher Chaftari, Sai-Ching Jim Yeung. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterology Report 2020; 8(1): 25 doi: 10.1093/gastro/goz065
|
| 107 |
Hikaru Ishihara, Tatsuyuki Watanabe, Shinsuke Kumei, Keiichiro Kume, Ichiro Yoshikawa, Masaru Harada. A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte–monocyte apheresis combination therapy. Clinical Journal of Gastroenterology 2024; 17(1): 46 doi: 10.1007/s12328-023-01887-7
|
| 108 |
Paul T. Kröner, Kabir Mody, Francis A. Farraye. Immune checkpoint inhibitor–related luminal GI adverse events. Gastrointestinal Endoscopy 2019; 90(6): 881 doi: 10.1016/j.gie.2019.09.009
|
| 109 |
Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu, Xuelei Ma. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.800879
|
| 110 |
Margaret Cupit-Link, Raja Khan, Alberto Pappo, Sara Helmig. Immune-related adverse events from immune checkpoint inhibitors in pediatric patients: A literature review and case series. EJC Paediatric Oncology 2023; 2: 100117 doi: 10.1016/j.ejcped.2023.100117
|
| 111 |
Aditi Saha, Isabella Dreyfuss, Humaira Sarfraz, Mark Friedman, Joseph Markowitz. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. Cancers 2022; 15(1): 84 doi: 10.3390/cancers15010084
|
| 112 |
David Anson, Joseph Norton, Benjamin Chaucer, Saurabh Bansal. Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation. Case Reports in Oncological Medicine 2019; 2019: 1 doi: 10.1155/2019/7896749
|
| 113 |
Ondřej Kubeček, Pavla Paterová, Martina Novosadová. Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. Life 2021; 11(12): 1387 doi: 10.3390/life11121387
|
| 114 |
Davide Mangani, Dandan Yang, Ana C. Anderson. Learning from the nexus of autoimmunity and cancer. Immunity 2023; 56(2): 256 doi: 10.1016/j.immuni.2023.01.022
|
| 115 |
C. Mehmet Hendekli. Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity. Journal of Cancer Research and Clinical Oncology 2023; 149(11): 9375 doi: 10.1007/s00432-023-04718-x
|
| 116 |
Ying-Chun Lo, Christina Price, Kim Blenman, Pallavi Patil, Xuchen Zhang, Marie E Robert. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal of Clinical Pathology 2021; 156(2): 214 doi: 10.1093/ajcp/aqaa217
|
| 117 |
Maria Zulfiqar, Christine Menias, Anup Shetty, Daniel R. Ludwig, Sana Saif Ur Rehman, Hilary Orlowski, Vincent Mellnick. Imaging Spectrum of Infections in the Setting of Immunotherapy and Molecular Targeted Therapy. Current Problems in Diagnostic Radiology 2022; 51(1): 86 doi: 10.1067/j.cpradiol.2020.11.006
|
| 118 |
Antigona Ulndreaj, Davor Brinc, Mehmet Altan, Oscar D. Pons-Belda, Amaia Fernandez-Uriarte, Hong Mu-Mosley, Farjana Fattah, Mitchell S. von Itzstein, Antoninus Soosaipillai, Vathany Kulasingam, Nicolas L. Palaskas, David E. Gerber, Eleftherios P. Diamandis, John V. Heymach, Ioannis Prassas. Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study. Clinical Chemistry and Laboratory Medicine (CCLM) 2023; 61(1): 154 doi: 10.1515/cclm-2022-0471
|
| 119 |
Stratigoula Sakellariou, Dionysia N. Zouki, Dimitrios C. Ziogas, Despoina Pouloudi, Helen Gogas, Ioanna Delladetsima. Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01812-7
|
| 120 |
Sarah F. Wesley, Aya Haggiagi, Kiran T. Thakur, Philip L. De Jager. Neurological Immunotoxicity from Cancer Treatment. International Journal of Molecular Sciences 2021; 22(13): 6716 doi: 10.3390/ijms22136716
|
| 121 |
Giovanni Cappello, Francesca Molea, Delia Campanella, Francesca Galioto, Filippo Russo, Daniele Regge. Gastrointestinal adverse events of immunotherapy. BJR|Open 2021; 3(1) doi: 10.1259/bjro.20210027
|
| 122 |
Natasha Klemm, Roberto Trasolini, Daljeet Chahal, Fergal Donnellan. Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis. Clinics and Research in Hepatology and Gastroenterology 2021; 45(4): 101604 doi: 10.1016/j.clinre.2020.101604
|
| 123 |
Giorgia Renga, Marina M Bellet, Marilena Pariano, Marco Gargaro, Claudia Stincardini, Fiorella D’Onofrio, Paolo Mosci, Stefano Brancorsini, Andrea Bartoli, Allan L Goldstein, Enrico Garaci, Luigina Romani, Claudio Costantini. Thymosin α1 protects from CTLA-4 intestinal immunopathology. Life Science Alliance 2020; 3(10): e202000662 doi: 10.26508/lsa.202000662
|
| 124 |
Hua Li, Zhi-Yan Fu, Mustafa Erdem Arslan, Daniel Cho, Hwajeong Lee. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. World Journal of Experimental Medicine 2021; 11(6): 79-92 doi: 10.5493/wjem.v11.i6.79
|
| 125 |
Tatsushi Naito, Takuto Nosaka, Kazuto Takahashi, Kazuya Ofuji, Hidetaka Matsuda, Masahiro Ohtani, Katsushi Hiramatsu, Yoshiaki Imamura, Tamotsu Ishizuka, Yasunari Nakamoto. A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis. Clinical Journal of Gastroenterology 2021; 14(5): 1431 doi: 10.1007/s12328-021-01459-7
|
| 126 |
Haleh Vaziri, Alla Turshudzhyan, Eric Vecchio. Immunotherapy-induced Colitis. Journal of Clinical Gastroenterology 2022; 56(7): 555 doi: 10.1097/MCG.0000000000001705
|
| 127 |
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Läubli. Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for ImmunoTherapy of Cancer 2024; 12(1): e007409 doi: 10.1136/jitc-2023-007409
|
| 128 |
Anas Khouri, Cesar Moreno, Benjamin Niland, Hirotada Akiho. New-Onset Crohn’s Disease following Initiation of Secukinumab: A Case Report and Review of the Role of IL-17 in the Pathogenesis of Crohn’s Disease. Case Reports in Gastrointestinal Medicine 2023; 2023: 1 doi: 10.1155/2023/1769290
|
| 129 |
Badal C. Roy, Ishfaq Ahmed, Jason Stubbs, Jun Zhang, Thomas Attard, Seth Septer, Danny Welch, Shrikant Anant, Venkatesh Sampath, Shahid Umar. DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis. Cell Death Discovery 2021; 7(1) doi: 10.1038/s41420-021-00526-9
|
| 130 |
Briette Karanfilian, Ishita Dalal, Abhishek Bhurwal, Anish Vinit Patel. Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab. American Journal of Therapeutics 2020; 27(4): e415 doi: 10.1097/MJT.0000000000001165
|
| 131 |
Natalie Farha, Joseph Sleiman, Pauline Funchain, Jessica Philpott. Immune Checkpoint Inhibitor Use in Microscopic Colitis. Annals of Internal Medicine: Clinical Cases 2022; 1(4) doi: 10.7326/aimcc.2022.0207
|
| 132 |
Istvan Bojti, Qianqi Wang, Tibor Bojti, Felicitas Bojti, Patrick Malcolm Siegel, Timo Heidt, Martin Moser, Christoph Bode, Dirk Westermann, Karlheinz Peter, Philipp Diehl. An Activation-Specific Anti-Mac-1 Designed-Ankyrin-Repeat-Protein Attenuates Colitis in Mice. Life 2023; 13(7): 1464 doi: 10.3390/life13071464
|
| 133 |
Majd Issa, Joy Tang, Yizhen Guo, Chris Coss, Thomas A. Mace, Jason Bischof, Mitch Phelps, Carolyn J Presley, Dwight H Owen. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Review of Anticancer Therapy 2022; 22(8): 861 doi: 10.1080/14737140.2022.2094772
|
| 134 |
Antonella Gallo, Rosa Talerico, Luca Novello, Maria Cristina Giustiniani, Ettore D’Argento, Emilio Bria, Massimo Montalto. Collagenous colitis and atezolizumab therapy: an atypical case. Clinical Journal of Gastroenterology 2021; 14(1): 165 doi: 10.1007/s12328-020-01276-4
|
| 135 |
Leonid Roshkovan, Sharyn I. Katz. NK Cells in Cancer Immunotherapy: Successes and Challenges. 2023; : 239 doi: 10.1016/B978-0-12-822620-9.00019-7
|
| 136 |
Gerard Grau, Ariadna Altadill, Eduard Brunet-Mas, Xavier Calvet. Cyclosporine treatment for severe steroid refractory immune-mediated colitis in a patient with ulcerative colitis. Gastroenterología y Hepatología 2024; 47(1): 72 doi: 10.1016/j.gastrohep.2023.01.005
|
| 137 |
Mariko Kurokawa, Ryo Kurokawa, Akifumi Hagiwara, Wataru Gonoi, Shinjiro Harayama, Koichi Koizumi, Koji Yoshino, Tsunekazu Hishima, Akira Baba, Yoshiaki Ota, Osamu Abe, Yasunobu Takaki. CT imaging findings of anti-PD-1 inhibitor-related enterocolitis.. Abdominal Radiology 2021; 46(7): 3033 doi: 10.1007/s00261-021-02986-0
|
| 138 |
Jessica Kimmel, Jordan Axelrad. The Complex Interplay Between Inflammatory Bowel Disease and Malignancy. Current Gastroenterology Reports 2020; 22(3) doi: 10.1007/s11894-020-0747-9
|
| 139 |
O. Gómez Escudero. Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 89 doi: 10.1016/j.rgmxen.2023.11.001
|
| 140 |
Ian A. Strohbehn, Meghan Lee, Harish Seethapathy, Donald Chute, Osama Rahma, Amanda Guidon, Tomas G. Neilan, Daniel A. Zlotoff, Daniel Okin, Michelle Rengarajan, Kerry Reynolds, Meghan E. Sise. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. American Journal of Kidney Diseases 2020; 76(2): 299 doi: 10.1053/j.ajkd.2020.02.451
|
| 141 |
Yingying Hu, Jian Gong, Lifu Zhang, Xiaolin Li, Xina Li, Bin Zhao, Xin Hai. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. International Immunopharmacology 2020; 84: 106601 doi: 10.1016/j.intimp.2020.106601
|
| 142 |
David Dora, Syeda Mahak Zahra Bokhari, Kenan Aloss, Peter Takacs, Juliane Zsuzsanna Desnoix, György Szklenárik, Patrick Deniz Hurley, Zoltan Lohinai. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. International Journal of Molecular Sciences 2023; 24(3): 2769 doi: 10.3390/ijms24032769
|
| 143 |
Tuan Tran, Nguyen Giang Tien Tran, Vincent Ho. Checkpoint Inhibitors and the Gut. Journal of Clinical Medicine 2022; 11(3): 824 doi: 10.3390/jcm11030824
|
| 144 |
Elizabeth A. Connolly, Tim Walker, Andre Van der Westhuizen. Impending infliximab access crisis: a case of steroid‐refractory, relapsing immunotherapy‐induced colitis responsive to infliximab. Internal Medicine Journal 2020; 50(6): 767 doi: 10.1111/imj.14854
|
| 145 |
Abigail L. Reens, Damien J. Cabral, Xue Liang, James E. Norton, Alex G. Therien, Daria J. Hazuda, Gokul Swaminathan. Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.643255
|
| 146 |
Lina Irshaid, Marie E. Robert, Xuchen Zhang. Immune Checkpoint Inhibitor–Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Archives of Pathology & Laboratory Medicine 2021; 145(2): 191 doi: 10.5858/arpa.2019-0700-OA
|
| 147 |
Matthew J. Townsend, Isaac J. Benque, Michael Li, Shilpa Grover. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors. Alimentary Pharmacology & Therapeutics 2024; doi: 10.1111/apt.17980
|
| 148 |
Mungyo Jung, Mikyung Kang, Byung‐Seok Kim, Jihye Hong, Cheesue Kim, Choong‐Hyun Koh, Garam Choi, Yeonseok Chung, Byung‐Soo Kim. Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects. Advanced Materials 2022; 34(9) doi: 10.1002/adma.202106516
|
| 149 |
Yousef R. Badran, Justine V. Cohen, Priscilla K. Brastianos, Aparna R. Parikh, Theodore S. Hong, Michael Dougan. Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. Journal for ImmunoTherapy of Cancer 2019; 7(1) doi: 10.1186/s40425-019-0711-0
|
| 150 |
Yasuhito Kunogi, Keiichi Tominaga, Keiichiro Abe, Mimari Kanazawa, Takanao Tanaka, Shoko Watanabe, Masayuki Kondo, Akira Kanamori, Makoto Iijima, Kenichi Goda, Yumi Nozawa, Kazuyuki Ishida, Atsushi Irisawa. Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare 2021; 9(4): 418 doi: 10.3390/healthcare9040418
|
| 151 |
Beatriz Frade-Sosa, Chafik Alejandro Chacur, Josep M. Augé, Andrés Ponce, Juan C. Sarmiento-Monroy, Ana Belén Azuaga, Nuria Sapena, Julio Ramírez, Virginia Ruiz-Esquide, Rosa Morlà, Sandra Farietta, Patricia Corzo, Juan D. Cañete, Raimon Sanmartí, José A. Gómez-Puerta. Calprotectin in Patients with Rheumatic Immunomediated Adverse Effects Induced by Checkpoints Inhibitors. Cancers 2023; 15(11): 2984 doi: 10.3390/cancers15112984
|
| 152 |
Adham Obeidat, Krixie Silangcruz, Landon Kozai, Eric Wien, Yu Fujiwara, Yoshito Nishimura. Clinical Characteristics and Outcomes of Gastritis Associated With Immune Checkpoint Inhibitors: Scoping Review. Journal of Immunotherapy 2022; 45(8): 363 doi: 10.1097/CJI.0000000000000435
|
| 153 |
Sara Kiparizoska, Megan E. Murphy, Mark C. Mattar. Check this out: treatment paradigms in immune-checkpoint inhibitor colitis. Current Opinion in Gastroenterology 2023; 39(1): 43 doi: 10.1097/MOG.0000000000000892
|
| 154 |
Avinash Rao Ullur, Gabrielle Côté, Karyne Pelletier, Abhijat Kitchlu. Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. Clinical Kidney Journal 2023; 16(6): 939 doi: 10.1093/ckj/sfad014
|
| 155 |
Suniti Bhaumik, Michel Edwar Mickael, Monica Moran, Marion Spell, Rajatava Basu. RORγt Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells. The Journal of Immunology 2021; 207(8): 2027 doi: 10.4049/jimmunol.2100175
|
| 156 |
Antonio Pizuorno Machado, Malek Shatila, Isabella C. Glitza Oliva, Mehmet Altan, Bilal Siddiqui, Yan Zhou, Krishnavathana Varatharajalu, Hao Chi Zhang, Anusha Thomas, Yinghong Wang. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. American Journal of Clinical Oncology 2023; 46(8): 360 doi: 10.1097/COC.0000000000001016
|
| 157 |
Kin Man Au, Justin E. Wilson, Jenny P.-Y. Ting, Andrew Z. Wang. An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis. Nature Biomedical Engineering 2023; doi: 10.1038/s41551-023-01136-9
|
| 158 |
Matthias Zellweger, Gerhard Rogler, Paul Komminoth, Lucas Werth, Matthias Breidert. Management einer persistierenden Kolitis nach erfolgreicher Immuntherapie eines nicht-kleinzelligen Karzinoms der Lunge. Zeitschrift für Gastroenterologie 2022; 60(07): 1124 doi: 10.1055/a-1652-2638
|
| 159 |
Georgios I. Papageorgiou, Evangelos Fergadis, Nikos Skouteris, Evridiki Christakos, Sergios A. Tsakatikas, Aikaterini Filippakou, Evangelia Papantoni, Gabriela Stanc, Efthymia Souka, Christos Valavanis, Christos Kosmas. Perforated appendicitis induced by pembrolizumab: a case report and review of the literature. Anti-Cancer Drugs 2022; 33(2): 208 doi: 10.1097/CAD.0000000000001247
|
| 160 |
Stephanie Steiger, Vincent Marcucci, Vidisha Desai, Min Zheng, Glenn Parker. Refractory Fulminant Colitis Requiring Surgical Intervention in a Patient With Ulcerative Colitis on Atezolizumab Therapy for Small Cell Lung Cancer: An Atypical Case. Cureus 2022; doi: 10.7759/cureus.25437
|
| 161 |
Manreet Randhawa, Gregory Gaughran, Christine Archer, Paul Pavli, Adrienne Morey, Sayed Ali, Desmond Yip. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World Journal of Clinical Oncology 2019; 10(10): 349 doi: 10.5306/wjco.v10.i10.349
|
| 162 |
Patricia Sanz-Segura, Paula García-Cámara, Eva Fernández-Bonilla, José Miguel Arbonés-Mainar, Vanesa Bernal Monterde. Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. Gastroenterología y Hepatología (English Edition) 2021; 44(4): 261 doi: 10.1016/j.gastre.2020.07.007
|
| 163 |
Manreet Randhawa, Gregory Gaughran, Christine Archer, Paul Pavli, Adrienne Morey, Sayed Ali, Desmond Yip. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World Journal of Clinical Oncology 2019; 10(10): 350-357 doi: 10.5306/wjco.v10.i10.350
|
| 164 |
Shohei Moriyama, Mitsuhiro Fukata, Ryoma Tatsumoto, Mihoko Kono, Matteo Cameli, Rami Riziq Yousef Abumuaileq, Constantinos Bakogiannis, Stefan Simovic, Ross Thomson. Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report. European Heart Journal - Case Reports 2021; 5(1) doi: 10.1093/ehjcr/ytab002
|
| 165 |
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, Marina Cipullo, Mario Romeo, Giovanna Palladino, Patrizia Iodice, Alessandro Federico, Teresa Troiani. The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review. Cancers 2024; 16(3): 611 doi: 10.3390/cancers16030611
|
| 166 |
Terufumi Kubo, Yoshihiko Hirohashi, Yoshiko Keira, Mayuko Akimoto, Tatsuru Ikeda, Noriaki Kikuchi, Hiroyuki Iwaki, Tomoki Kikuchi, Masahiko Obata, Rena Morita, Kiyoshi Kasai, Keiko Segawa, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yasuhiro Kikuchi, Tomoyo Shinkawa, Tadashi Hasegawa, Toshihiko Torigoe. Identification of characteristic subepithelial surface granulomatosis in immune‐related adverse event‐associated enterocolitis. Cancer Science 2021; 112(3): 1320 doi: 10.1111/cas.14773
|